COMMITMENTS AND CONTINGENCIES (Details Narrative)
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
|
Dec. 05, 2022
USD ($)
shares
|
Aug. 16, 2022
$ / shares
shares
|
Dec. 31, 2021
USD ($)
|
Dec. 10, 2021
USD ($)
|
Jun. 10, 2021
ft²
|
Jan. 01, 2021
USD ($)
|
Sep. 24, 2020
USD ($)
$ / shares
|
Jul. 05, 2020
USD ($)
$ / shares
shares
|
Jun. 05, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2019 |
Mar. 31, 2018
USD ($)
|
Sep. 30, 2006
USD ($)
|
Dec. 31, 2022
USD ($)
shares
|
Sep. 30, 2022
USD ($)
shares
|
Sep. 30, 2017
USD ($)
shares
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options aggregate | shares |
|
|
|
|
|
|
|
|
|
|
|
|
1,901,410,519
|
1,901,410,519
|
|
| Accrued consulting fees |
|
|
|
|
|
|
|
|
|
|
|
|
$ 6,000
|
$ 12,000
|
|
| Consideration liability |
|
|
|
|
|
|
|
|
|
|
|
|
80,240
|
78,440
|
|
| Notes payables |
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
40,000
|
|
| Accrued interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
40,240
|
38,440
|
|
| Litigation settlement number of shares | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
| Litigation settlement shares, value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,000
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss contingency damages sought value |
|
|
|
$ 100,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Busch Employment Agreement [Member]. | Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accrued director compensation |
|
|
|
|
|
|
|
|
|
|
|
|
207,500
|
192,500
|
|
| Consulting Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation fees |
|
|
|
|
|
$ 2,000
|
|
|
|
|
|
|
|
|
|
| Exclusive License Agreement [Member] | George Mason University [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense |
|
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
|
|
1.50%
|
|
|
|
| Advance royalties |
|
|
|
|
|
|
|
|
|
|
|
|
2,526
|
2,443
|
|
| Exclusive License Agreement [Member] | Sublicense Royalty [Member] | George Mason University [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
|
|
15.00%
|
|
|
|
| License Agreement [Member] | National Institutes of Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expense |
|
|
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
|
300.00%
|
|
|
|
|
| Advance royalties |
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
| License Agreement [Member] | Sublicense Royalty [Member] | National Institutes of Health [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue percentage |
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
| Lease Agreements [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lessee operating lease description |
|
|
|
|
|
|
|
|
|
In
December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is
for a period of 61 months, with an option to extend, commencing in February 2020 and expiring in February 2025
|
|
|
|
|
|
| Lease period |
|
|
|
|
|
|
|
|
|
61 months
|
|
|
|
|
|
| Lease Amendment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rentable square feet | ft² |
|
|
|
|
4,734
|
|
|
|
|
|
|
|
|
|
|
| Monthly rent, description |
|
|
|
|
the Company must pay a total annual base rent of; (1) $115,823 for year one; (2) $119,310 for year two; (3) $122,893
for year three; (4) $126,580 for year four; (5) $130,377 for year five; (6) $135,163 for year six; (7) $139,218 for year seven; (8) $143,394
for year eight; (9) $147,696 for year nine; (10) $152,127 for year ten; (11) $156,331 for year eleven; (12) $161,391 for year twelve;
(13) $166,233 for year thirteen; (14) $171,220 for year fourteen and; (15) $176,357 for year fifteen
|
|
|
|
|
|
|
|
|
|
|
| Dr. Michael Ruxin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Annual base salary |
|
|
|
|
|
|
|
|
|
|
|
|
125,000
|
$ 112,500
|
|
| Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salaries |
|
|
|
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
| Annual decretionary bonus percentage |
|
|
|
|
|
|
|
|
150.00%
|
|
|
|
|
|
|
| Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] | 2022 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock, shares | shares |
|
49,047,059
|
|
|
|
|
|
|
49,047,059
|
|
|
|
|
|
|
| Stock options granted | shares |
|
420,691,653
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options aggregate | shares |
|
469,738,712
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
$ 0.0036
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dr. Michael Ruxin [Member] | Ruxin Employment Agreement [Member] | 2022 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
|
|
420,691,653
|
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salaries |
|
|
|
|
|
|
|
|
$ 60,000
|
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
420,691,653
|
|
|
|
|
|
|
420,691,653
|
|
|
|
|
|
|
| Jeffrey Busch [Member] | Busch Employment Agreement [Member]. | 2020 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock, shares | shares |
|
49,047,059
|
|
|
|
|
|
|
49,047,059
|
|
|
|
|
|
|
| Stock options aggregate | shares |
|
|
|
|
|
|
|
|
469,738,712
|
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred compensation arrangements overall description |
|
|
The Board also approved two
new bonuses for which Mr. Chilcott was eligible: (i) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $1,000,000; and (ii) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $2,000,000
in the aggregate. On December 6, 2022, the Board approved a bonus compensation plan pursuant to which Thomas E. Chilcott, III, the Company’s Chief Financial Officer, was eligible for: (i) a $150,000 bonus payable upon the successful
filing of the Company’s report on Form 10-K for the annual period ended September 30, 2022 (the “ Annual Report ”) on or before December 29, 2022; or (ii) a $100,000 bonus payable upon the successful filing of the Company’s Annual Report on or
before January 13, 2023 (collectively, the “Bonus”)
|
|
|
|
|
|
|
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salaries |
|
|
|
|
|
|
|
|
|
|
|
|
$ 150,000
|
|
|
| Annual base salary |
|
|
$ 225,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salaries |
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Thomas E Chilcott, III [Member] | Offer Letter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salaries |
|
|
|
|
|
|
$ 225,000
|
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
|
|
|
| Deferred compensation arrangements overall description |
|
|
|
|
|
|
Mr. Chilcott is entitled to participate
in all medical and other benefits that the Company has established for its employees. The offer letter also provides that Mr. Chilcott
will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock which were granted on August 16, 2022
with an exercise price of $0.0036 and an expiration date of August 15, 2032 and subject to vesting terms
|
|
|
|
|
|
|
|
|
| Zaslavsky [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salaries |
$ 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Base salary percentage |
35.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zaslavsky [Member] | Share-Based Payment Arrangement, Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sharebased compensation available for grant | shares |
150,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vesting percentage |
20.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consultant [Member] | Scientific Advisory Board Service Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation fees |
|
|
|
|
|
|
|
$ 2,000
|
|
|
|
|
|
|
|
| Payments for fees |
|
|
|
|
|
|
|
$ 1,500
|
|
|
|
|
|
|
|
| Consultant [Member] | Scientific Advisory Board Service Agreement [Member] | 2022 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
|
88,786,943
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
|
|
| Consultant [Member] | Pathology Advisory Board Service Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation fees |
|
|
|
|
|
|
|
$ 272
|
|
|
|
|
|
|
|
| Consultant [Member] | Pathology Advisory Board Service Agreement [Member] | 2022 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options granted | shares |
|
|
|
|
|
|
|
77,972,192
|
|
|
|
|
|
|
|
| Stock options exercise price | $ / shares |
|
|
|
|
|
|
|
$ 0.0036
|
|
|
|
|
|
|
|